KR100661774B1 - 광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도 - Google Patents

광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도 Download PDF

Info

Publication number
KR100661774B1
KR100661774B1 KR1020017002870A KR20017002870A KR100661774B1 KR 100661774 B1 KR100661774 B1 KR 100661774B1 KR 1020017002870 A KR1020017002870 A KR 1020017002870A KR 20017002870 A KR20017002870 A KR 20017002870A KR 100661774 B1 KR100661774 B1 KR 100661774B1
Authority
KR
South Korea
Prior art keywords
pyridyl
piperidinyl
dihydro
methyl
oxadiazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017002870A
Other languages
English (en)
Korean (ko)
Other versions
KR20010073129A (ko
Inventor
안드레아 제드나코비츠
라스즐로 유로그디
라스즐로 데네스
이스트반 쿠르츠
에데 마르반요오스
미할리 바라바스
에르노 박시
즈스즈산나 코롬
졸탄 나기
라스즐로 유르게
제노 스질베레키
카롤리 악사이
피터 크라즈시
지타 스사카이
마그돌나 토로크
Original Assignee
비오렉스 쿠타토 에쉬 훼레스테 에르테
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비오렉스 쿠타토 에쉬 훼레스테 에르테 filed Critical 비오렉스 쿠타토 에쉬 훼레스테 에르테
Publication of KR20010073129A publication Critical patent/KR20010073129A/ko
Application granted granted Critical
Publication of KR100661774B1 publication Critical patent/KR100661774B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020017002870A 1998-12-14 1999-12-07 광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도 Expired - Fee Related KR100661774B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9802897 1998-12-14
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient

Publications (2)

Publication Number Publication Date
KR20010073129A KR20010073129A (ko) 2001-07-31
KR100661774B1 true KR100661774B1 (ko) 2006-12-28

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017002870A Expired - Fee Related KR100661774B1 (ko) 1998-12-14 1999-12-07 광학적 활성 피리딜-4에이치-1,2,4-옥사디아진 유도체 및이것의 혈관 질환의 치료에서의 용도

Country Status (27)

Country Link
US (1) US6384029B1 (enExample)
EP (1) EP1147105B1 (enExample)
JP (2) JP2002532498A (enExample)
KR (1) KR100661774B1 (enExample)
AT (1) ATE266027T1 (enExample)
AU (1) AU765336B2 (enExample)
BG (1) BG65179B1 (enExample)
BR (1) BR9913982A (enExample)
CA (1) CA2340734C (enExample)
CZ (1) CZ300764B6 (enExample)
DE (1) DE69917074T2 (enExample)
DK (1) DK1147105T3 (enExample)
EE (1) EE04551B1 (enExample)
ES (1) ES2219091T3 (enExample)
HR (1) HRP20010133B1 (enExample)
HU (1) HU226617B1 (enExample)
IL (1) IL141515A (enExample)
NO (1) NO317649B1 (enExample)
PL (1) PL196584B1 (enExample)
PT (1) PT1147105E (enExample)
RS (1) RS50129B (enExample)
RU (1) RU2222538C2 (enExample)
SI (1) SI1147105T1 (enExample)
SK (1) SK285582B6 (enExample)
UA (1) UA70340C2 (enExample)
WO (1) WO2000035914A1 (enExample)
ZA (1) ZA200101182B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2320330C2 (ru) 2002-01-11 2008-03-27 СиУайТиАрЭкс КОРПОРЕЙШН Производные карбоксамидина и их использование при лечении заболеваний сосудов
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
ES2385735T3 (es) 2008-06-26 2012-07-31 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
BRPI0919867A2 (pt) 2008-11-18 2015-12-15 Santen Pharmaceutical Co Ltd agente terapeutico ou profilatico para uma doenca degenerativa coriorretiniana, e metodo profilatico ou terapeutico para uma doenca degenerativa coriorrentiniana
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
DK3193840T3 (da) 2014-09-15 2021-08-16 Orphazyme As Arimoclomol-formulering
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
EP3630105A1 (en) 2017-05-24 2020-04-08 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
EP0858413B1 (en) * 1995-11-03 2003-05-21 Summit Packaging Systems Limited Apparatus for dispensing and filling bags at a checkout counter of a supermarket
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
DK1147105T3 (da) 2004-06-01
HRP20010133B1 (en) 2005-02-28
CZ20011550A3 (cs) 2001-08-15
AU1790600A (en) 2000-07-03
YU25001A (sh) 2004-07-15
PT1147105E (pt) 2004-07-30
EP1147105A1 (en) 2001-10-24
ATE266027T1 (de) 2004-05-15
HUP9802897A2 (hu) 2000-11-28
JP5620340B2 (ja) 2014-11-05
BG105342A (en) 2001-12-29
SK285582B6 (sk) 2007-04-05
NO20012310D0 (no) 2001-05-10
CZ300764B6 (cs) 2009-08-05
HU226617B1 (en) 2009-04-28
IL141515A (en) 2005-09-25
HRP20010133A2 (en) 2002-02-28
JP2002532498A (ja) 2002-10-02
SK2342001A3 (en) 2001-08-06
PL196584B1 (pl) 2008-01-31
KR20010073129A (ko) 2001-07-31
PL346767A1 (en) 2002-02-25
UA70340C2 (en) 2004-10-15
RS50129B (sr) 2009-03-25
EE04551B1 (et) 2005-10-17
NO317649B1 (no) 2004-11-29
EP1147105B1 (en) 2004-05-06
ES2219091T3 (es) 2004-11-16
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
ZA200101182B (en) 2002-02-12
AU765336B2 (en) 2003-09-18
JP2011201916A (ja) 2011-10-13
CA2340734A1 (en) 2000-06-22
DE69917074D1 (de) 2004-06-09
EE200100188A (et) 2002-08-15
DE69917074T2 (de) 2005-05-12
NO20012310L (no) 2001-05-10
BG65179B1 (bg) 2007-05-31
US6384029B1 (en) 2002-05-07
IL141515A0 (en) 2002-03-10
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
BR9913982A (pt) 2001-06-12
CA2340734C (en) 2008-10-21
WO2000035914A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
JP5620340B2 (ja) 光学活性ピリジル−４ｈ−１，２，４−オキサジアジン誘導体およびその血管疾患の治療における使用
JP4316794B2 (ja) イソキノリン誘導体及び医薬
KR890002290B1 (ko) 피페라진 유도체 및 그의 제조방법
JP2011201916A5 (enExample)
JPWO1999020620A1 (ja) イソキノリン誘導体及び医薬
JPH05208957A (ja) 新規ｒ−及びｓ−カルバゾール誘導体
US20090253690A1 (en) Pharmaceutically effective compounds
CA1223583A (en) 1,5-benzothiozepines with cardiovascular activity, methods for their preparations and pharmaceutical compositions containing them
RU2130019C1 (ru) Производные 3(2н)-пиридазинона, фармацевтическая композиция, способ лечения
US4751246A (en) Compositions and method
NO762778L (enExample)
JPH05186459A (ja) ２−アミノ−５−シアノ−４−キノリン−１，４−ジヒドロピリジン類
CA2165503A1 (en) 1,4-benzoxazine derivative, pharmaceutical composition containing the same and use thereof
FR2599033A1 (fr) Derives des 3-(hydroxymethyl)-isoquinoleine, procede pour les preparer et compositions pharmaceutiques les contenant
US4224335A (en) Tetrahydrocarbazoles and their use
KR910004674B1 (ko) 부정맥치료제
FI76319C (fi) Foerfarande foer framstaellning av nya substituerade 3-fenoxi-1-alkoxikarbonyl-alkylamino-propanol-2 -foereningar med -receptor haemmande verkan.
JPH02135A (ja) 多還式化合物とこれを含有する医薬組成物
JP2001114699A (ja) キマーゼ阻害作用を有する化合物を有効成分とする血管新生阻害剤
BE856055A (fr) Derives de 4-hydroxyphenylalcanolamine et leur preparation

Legal Events

Date Code Title Description
R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20101214

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111221

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111221

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000